Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed

{Purpose Cisplatin-pemetrexed is the first-line chemotherapy for advanced, metastatic non-squamous non-small cell lung cancer (NSCLC), but the risk of kidney toxicity limits the therapeutic schedule. We performed a retrospective study of patient survival at 1 year and glomerular filtration rate (GFR) outcomes in cisplatin-pemetrexed-treated NSCLC patients. Methods Patients (P) treated for NSCLC between 2008 and 2014 were divided into two groups according to GFR at diagnosis: G1 (GFR >= 90 mL/min/1.73 m(2)) and G2 (GFR between 60 and 89 mL/min/1.73 m(2)). GFR were compared in the two groups at 3 and 12 months. The following statistical methods were used: multivariate generalized estimating equation model for GFR outcome, Kaplan-Meier method for patient survival rate, and Cox model for analysing survival criteria. Results A total of 112 patients were included in the study (G1 = 87 P